RINVOQ can be taken as monotherapy or in combination with methotrexate.1
Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.
- RINVOQ (upadacitinib) Summary of Product Characteristics, available at www.medicines.ie.
Date of preparation: June 2020 IE-RNQR-200012
RINVOQ HUMIRA – Legal Category: POM (S1A).
Further information is available on request from AbbVie Limited, 14 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, website: www.hpra.ie